Mindera Health™ Announces Issuance of Additional International Patent Coverage for Dermal Biomarker Patch Platform

Mindera Health, a precision medicine company developing personalized tools to optimize patient outcomes, today announced that additional patent protection has been issued in Japan for the core technology behind the dermal biomarker patch.

Japanese patent number JP7572774 was issued October 16, 2024 and describes devices that can extract dermal biomarkers in situ. The inventors discovered that a covalently modified patch can efficiently capture and extract meaningful quantities of biomarkers from the skin. This patent adds to existing patent protection for the dermal biomarker patch technology in the United States, Europe, Australia, China, Hong Kong, and Korea. This brings the total number of issued or allowed patents related to the Company’s dermal biomarker patch technology to 11.

“We are pleased to have been issued additional patent coverage in Japan for the Dermal Biomarker Patch,” said Tobin Dickerson, Mindera Health’s chief scientific officer and co-founder. “This technology underpins tests such as Mind.Px™, a test designed to optimize psoriasis biologic treatment decisions and reduce trial and error treatment paradigms. As we expand the platform into other indications, we aim to more broadly bring precision medicine to dermatology.”

About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

About Mind.Px™
Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[i]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annually.[ii]

  1. Bagel J, Wang Y, Montgomery P 111, et al. A machine learning-based test for predicting response to psoriasis biologics. SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5
  2. Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

Mindera Health™ becomes a Medi-Cal™ Credentialled Provider

Provider status with Medi-Cal will allow Mindera Health to provide its proprietary Mind.Px test to predict biologic class response in plaque psoriasis to the over 15 million Medi-Cal Beneficiaries.

San Diego, CA, Aug 19, 2024 (GLOBE NEWSWIRE) — Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has completed the credentialling process to become a Medi-Cal provider making its services available to the over 15 million Californians that rely on the state’s Medicaid program for health insurance coverage.

In the United States, psoriasis affects more than three percenti of the population. Moderate-to-severe disease severity accounts for approximately one-third of psoriasis diagnoses.ii This auto-immune condition often leads to absenteeism or major problems at work, depression, and other clinical comorbidities.ii Specialty drug spending for psoriasis is escalating exponentially, and biologics are often identified by payers, employers, and pharmacy benefit managers as being in their top drug expenditures each year.iii Furthermore, successful patient responses to currently available biologic treatments are roughly 52 percentiv, leading to trial-and-error treatment selection and increased healthcare costs.

Mind.Px is a predictive test that uses a patented dermal biomarker patch allowing for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value.v By leveraging precision medicine and matching the patient to the right drug class before treatment begins, clinical outcomes can be improved while biologic drug expenditures are optimized.

“We are delighted to have the opportunity to serve the 1 in 3 Californian’s insured as Medi-Cal beneficiaries,” says Ron Rocca, CEO of Mindera Health. “We look forward to partnering with the largest single payer in our home state and its affiliated managed care plans to address the rising costs and optimize clinical outcomes associated with biologic therapy in plaque psoriasis.”

About Medi-Cal™

According to the Californian Health Care Foundation, Medi-Cal, California’s Medicaid program, is the state’s health insurance program for Californians with low income, including nearly four in ten children, one in five nonelderly adults, and two million seniors and people with disabilities. In total, over 15 million Californians – one in three – rely on the program for coverage. Medi-Cal pays for essential primary care, specialty, acute, behavioral health and long-term care services.

About Mindera Health

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA- and CAP-certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

About Mind.Px™

Mind.Px is a predictive test that uses a dermal biomarker patch that allows for rapid and painless extraction of mRNA from skin, followed by transcriptomic analysis and machine learning-derived classifiers to provide actionable results for clinicians with >91 percent positive predictive value[v]. By matching the patient to the right drug class before treatment begins, a recent study used a budget impact model to predict the potential costs savings associated with Mind.Px and returned annual cost savings ranging from $5,138 to $13,141 per patient[vi].

I Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):10291072. doi:10.1016/j.jaad.2018.11.057.

ii Van Voorhees AS, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide, 7th ed. Table 2-3. https://psoriasis.org/the-pocket-guide.

iii Prime Therapeutics 2012-2015 and 2019-2020 posters titled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication.”

iv Enos CW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innovations. 2021;1:100025.

v Bagel J, Wang Y, Montgomery P III, et al. A machine learning-based test for predicting response to psoriasis biologics.SKIN The Journal of Cutaneous Medicine. 2021;5(6):621-638. doi:10.25251/skin.5.6.5

vi Wu J, Montgomery P, Long B, et al. An economic evaluation of the budget impact of precision medicine testing for the treatment of psoriasis. SKIN The Journal of Cutaneous Medicine. 2021;5(4):372-387. doi:10.25251/skin.5.4.6

Contact:
Scot Nelson

Mindera Health

scot.nelson@minderahealth.com

858-810-6070

Mindera Health™ Announces Contract With General Services Administration®

Mindera Corp dba Mindera Health today announced that the General Services Administration (GSA) has awarded a 5-year contract to Mindera Health, enabling access to the Mind.Px™ test for patients with plaque psoriasis considering biologic therapy.

San Diego, CA, Oct. 10, 2023 (GLOBE NEWSWIRE) — Mindera Health today announced that the General Services Administration (GSA) has granted a 5 year contract award to Mindera Health enabling access to their proprietary technology, Mind.Px. The Mind.Px test is the first and only test that provides a personalized approach selecting the class of biologic therapy a patient with plaque psoriasis is most likely to respond to. The decision is effective today and enables access to Mind.Px for those eligible for treatment at government-affiliated facilities including the over 9.6 million veterans, active duty, retirees and their families that are served by the Veteran’s Administration Health System and Department of Defense Medical Treatment Facilities, and others.

“Mind.Px addresses an unmet need in the effective management of plaque psoriasis patients by informing the selection of the most efficacious class of biologic therapy for a particular patient.” said Dr. Jeffrey Travers, Professor and Chair of Pharmacology and Toxicology and Professor of Dermatology at the Boonshoft School of Medicine at Wright State University and VA investigator at the Dayton VA Medical Center with no formal ties to Mindera Health. “This agreement will not only serve the patients that seek care in the VA and DOD Facilities, but will also afford the Dermatology Residents-in-training the opportunity to learn to manage psoriasis patients while leveraging this advance in personalized medicine.”

“We applaud the GSA/VA’s commitment to enabling access to new and innovative technologies like Mind.Px and are honored to participate in improving the care for psoriasis, while at the same time eliminating waste and improving cost-outcomes, within the largest integrated health network in the world,” said Ron Rocca CEO of Mindera Health.

About Mind.Px™
Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments.

About Mindera Health™
Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com.

You can learn more about Mind.Px at www.minderahealth.com or by emailing Mindera at mindpx@minderahealth.com.